The HP (high potency) APIs market size has grown strongly in recent years. It will grow from $25.2 billion in 2024 to $27.47 billion in 2025 at a compound annual growth rate (CAGR) of 9%. The growth in the historic period can be attributed to increasing demand for oncology therapies, rising emphasis of pharmaceutical companies on manufacturing of HP-APIS, a rise in healthcare awareness and expenditure, strong economic growth in emerging markets and increasing government initiatives.
The HP (high potency) APIs market size is expected to see strong growth in the next few years. It will grow to $39.81 billion in 2029 at a compound annual growth rate (CAGR) of 9.7%. The growth in the forecast period can be attributed to a rise in the number of cancer cases, growing focus on precision medicine and increasing ageing population will drive the growth. Major trends in the forecast period include focus on strategies such as production facility expansion and mergers and acquisitions, focus on increasing investments to grow HP-API production, use of artificial intelligence (ai) in manufacturing APIS, focus on green manufacturing and focus on launch of new, innovative products.
The growth of the HP (high potency) APIs market is driven by the increasing number of cancer cases and the concurrent rise in sales of cancer drugs. The surge in cancer incidence is leading to heightened research and development efforts for anticancer drugs, consequently fueling the demand for the market. According to the International Agency for Research on Cancer (IARC) report by the World Health Organization, the global cancer burden is anticipated to witness an increase of 29.5 million new cases and 16.4 million deaths by 2040. Notably, 70% of cancer-related deaths occur in middle and low-income countries. As a result, the escalating prevalence of cancer is expected to boost revenues for the HP (high potency) APIs market.
Government initiatives aimed at enhancing cancer care and treatment are poised to drive the future growth of the HP (high potency) APIs market. These initiatives encompass policies, funding, and programs implemented by governments to enhance the accessibility, affordability, and quality of care for individuals diagnosed with cancer. The importance of High Potency (HP) APIs in cancer treatment lies in their ability to target specific molecular pathways, thereby enhancing the effectiveness of therapies. An example is the revival of the Cancer Moonshot Initiative unveiled by President Biden in September 2023. The initiative, supported by the Centers for Disease Control and Prevention (CDC), aims to halve the cancer death rate within 25 years and provide comprehensive support to cancer survivors and their families. Consequently, government initiatives to improve cancer care and treatment are propelling the growth of the HP (high potency) APIs market.
Companies operating in the HP (high potency) APIs market are adopting strategies such as expanding production facilities and engaging in mergers and acquisitions to maintain their competitive positions. In June 2022, MilliporeSigma, a global life science business based in the US, inaugurated a $65 million facility for the production of high-potency active pharmaceutical ingredients (HPAPI), with a specific focus on cancer treatments.
Major players in the HP (high potency) APIs market are actively pursuing strategic partnerships to drive market revenues. Collaborations offer various advantages, including access to new technology, expanded customer choice, global servicing capabilities, a collaborative global platform, and integrated services. In March 2023, CatSci Ltd., a UK-based provider of innovative process research and development services, partnered with AGC Pharma Chemicals Europe S.L.U. This collaboration enables customers to access a broad range of manufacturing technologies, including fluorination and bromination. It also facilitates AGC Pharma Chemicals' customers to benefit from expertise in state-of-the-art chemical development and analytical development.
In May 2022, Astorg Partners, a capital market company based in France, acquired Corden Pharma for an undisclosed sum. Through this acquisition, Astorg intends to enhance its portfolio by leveraging Corden Pharma's expertise in supplying high potency (HP) APIs. Corden Pharma Colorado Corp is a company located in Germany that specializes in high potency (HP) APIs.
Major companies operating in the HP (high potency) APIs market include Merck KGaA, Pfizer, Inc, Thermo Fisher Scientific, Inc, Teva Pharmaceuticals, Lonza Group AG, Sanofi (EUROAPI), Corden Pharma International, Dr. Reddy’s Laboratories Ltd., Siegfried Holding AG, Novartis, Roche India, Arlak Biotech (India), Healthkind Labs Pvt. Ltd, Swisschem Healthcare Pvt. Ltd, Apikos Pharma, Kolaz Biotech, Cstone Pharma (China), Carsgen Therapeutics (China), Jw Therapeutics (China), Beigene(China), Takeda Pharmaceuticals (Japan), Astellas Pharma Inc (Japan), Otsuka Pharmaceutical Co, Ltd (Japan), Legend Biotech Co (China), Abbott Laboratories, Vectura Group (U.K), Almedis (Russia), Neuca, Farmacol, Polska Grupa Farmaceutyczna, Polpharma, Tzmo, Eli Lilly And Company, Bristol-Myers Squibb Company, Apotex, Gilead Sciences, Abbvie Inc, Hisun Usa Inc, GlaxoSmithKline, Amega Biotech, Biomarin Pharmaceutical, Ferring Pharmaceuticals, Tikun Olam Cannbit, Wavelength Pharmaceuticals, Saudibio, Tabuk Pharmaceuticals, Cipla, Bayer, Adcock Ingram, Johnson & Johnson, AstraZeneca Pharmaceutical (Pty) Ltd, Eurolab.
North America was the largest region in the global HP (high potency) APIS market in 2024. Middle East is expected to be the fastest growing region in the HP (high potency) APIS market report during the forecast period. The regions covered in the hp (high potency) APIS market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa. The countries covered in the hp (high potency) APIS market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Russia, South Korea, UK, USA, Italy, Canada, Spain.
High-potency APIs denote substances that, at very minimal doses, elicit a biological response. Traditionally, examples of HPAPIs include cytotoxic substances and sex hormones such as estrogen. While highly potent active pharmaceutical ingredients (HP APIs) in the market remain effective at significantly lower dosage levels compared to standard APIs, their potency presents distinctive handling challenges.
The primary categories within the high-potency APIs market are innovative HPAPI and generic HPAPI. Various synthesis types, including synthetic HPAPI and biotech HPAPI, find application in therapeutic areas such as oncology, hormonal disorders, glaucoma, and other medical fields such as respiratory disorders, cardiovascular disease (CVD), diabetes, cosmetology, and erectile dysfunction. Glaucoma comprises a group of eye diseases affecting the optic nerve, crucial for maintaining good vision.
The HP (high potency) APIs market research report is one of a series of new reports that provides HP (high potency) APIs market statistics, including HP (high potency) APIs industry global market size, regional shares, competitors with an HP (high potency) APIs market share, detailed HP (high potency) APIs market segments, market trends and opportunities, and any further data you may need to thrive in the HP (high potency) APIs industry. This HP (high potency) APIs market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenarios of the industry.
The market consists of sales of cytotoxic compounds and sex hormones. Values in this market are factory gate values, that is, the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors, and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.
The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD, unless otherwise specified).
The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.
This product will be delivered within 3-5 business days.
The HP (high potency) APIs market size is expected to see strong growth in the next few years. It will grow to $39.81 billion in 2029 at a compound annual growth rate (CAGR) of 9.7%. The growth in the forecast period can be attributed to a rise in the number of cancer cases, growing focus on precision medicine and increasing ageing population will drive the growth. Major trends in the forecast period include focus on strategies such as production facility expansion and mergers and acquisitions, focus on increasing investments to grow HP-API production, use of artificial intelligence (ai) in manufacturing APIS, focus on green manufacturing and focus on launch of new, innovative products.
The growth of the HP (high potency) APIs market is driven by the increasing number of cancer cases and the concurrent rise in sales of cancer drugs. The surge in cancer incidence is leading to heightened research and development efforts for anticancer drugs, consequently fueling the demand for the market. According to the International Agency for Research on Cancer (IARC) report by the World Health Organization, the global cancer burden is anticipated to witness an increase of 29.5 million new cases and 16.4 million deaths by 2040. Notably, 70% of cancer-related deaths occur in middle and low-income countries. As a result, the escalating prevalence of cancer is expected to boost revenues for the HP (high potency) APIs market.
Government initiatives aimed at enhancing cancer care and treatment are poised to drive the future growth of the HP (high potency) APIs market. These initiatives encompass policies, funding, and programs implemented by governments to enhance the accessibility, affordability, and quality of care for individuals diagnosed with cancer. The importance of High Potency (HP) APIs in cancer treatment lies in their ability to target specific molecular pathways, thereby enhancing the effectiveness of therapies. An example is the revival of the Cancer Moonshot Initiative unveiled by President Biden in September 2023. The initiative, supported by the Centers for Disease Control and Prevention (CDC), aims to halve the cancer death rate within 25 years and provide comprehensive support to cancer survivors and their families. Consequently, government initiatives to improve cancer care and treatment are propelling the growth of the HP (high potency) APIs market.
Companies operating in the HP (high potency) APIs market are adopting strategies such as expanding production facilities and engaging in mergers and acquisitions to maintain their competitive positions. In June 2022, MilliporeSigma, a global life science business based in the US, inaugurated a $65 million facility for the production of high-potency active pharmaceutical ingredients (HPAPI), with a specific focus on cancer treatments.
Major players in the HP (high potency) APIs market are actively pursuing strategic partnerships to drive market revenues. Collaborations offer various advantages, including access to new technology, expanded customer choice, global servicing capabilities, a collaborative global platform, and integrated services. In March 2023, CatSci Ltd., a UK-based provider of innovative process research and development services, partnered with AGC Pharma Chemicals Europe S.L.U. This collaboration enables customers to access a broad range of manufacturing technologies, including fluorination and bromination. It also facilitates AGC Pharma Chemicals' customers to benefit from expertise in state-of-the-art chemical development and analytical development.
In May 2022, Astorg Partners, a capital market company based in France, acquired Corden Pharma for an undisclosed sum. Through this acquisition, Astorg intends to enhance its portfolio by leveraging Corden Pharma's expertise in supplying high potency (HP) APIs. Corden Pharma Colorado Corp is a company located in Germany that specializes in high potency (HP) APIs.
Major companies operating in the HP (high potency) APIs market include Merck KGaA, Pfizer, Inc, Thermo Fisher Scientific, Inc, Teva Pharmaceuticals, Lonza Group AG, Sanofi (EUROAPI), Corden Pharma International, Dr. Reddy’s Laboratories Ltd., Siegfried Holding AG, Novartis, Roche India, Arlak Biotech (India), Healthkind Labs Pvt. Ltd, Swisschem Healthcare Pvt. Ltd, Apikos Pharma, Kolaz Biotech, Cstone Pharma (China), Carsgen Therapeutics (China), Jw Therapeutics (China), Beigene(China), Takeda Pharmaceuticals (Japan), Astellas Pharma Inc (Japan), Otsuka Pharmaceutical Co, Ltd (Japan), Legend Biotech Co (China), Abbott Laboratories, Vectura Group (U.K), Almedis (Russia), Neuca, Farmacol, Polska Grupa Farmaceutyczna, Polpharma, Tzmo, Eli Lilly And Company, Bristol-Myers Squibb Company, Apotex, Gilead Sciences, Abbvie Inc, Hisun Usa Inc, GlaxoSmithKline, Amega Biotech, Biomarin Pharmaceutical, Ferring Pharmaceuticals, Tikun Olam Cannbit, Wavelength Pharmaceuticals, Saudibio, Tabuk Pharmaceuticals, Cipla, Bayer, Adcock Ingram, Johnson & Johnson, AstraZeneca Pharmaceutical (Pty) Ltd, Eurolab.
North America was the largest region in the global HP (high potency) APIS market in 2024. Middle East is expected to be the fastest growing region in the HP (high potency) APIS market report during the forecast period. The regions covered in the hp (high potency) APIS market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa. The countries covered in the hp (high potency) APIS market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Russia, South Korea, UK, USA, Italy, Canada, Spain.
High-potency APIs denote substances that, at very minimal doses, elicit a biological response. Traditionally, examples of HPAPIs include cytotoxic substances and sex hormones such as estrogen. While highly potent active pharmaceutical ingredients (HP APIs) in the market remain effective at significantly lower dosage levels compared to standard APIs, their potency presents distinctive handling challenges.
The primary categories within the high-potency APIs market are innovative HPAPI and generic HPAPI. Various synthesis types, including synthetic HPAPI and biotech HPAPI, find application in therapeutic areas such as oncology, hormonal disorders, glaucoma, and other medical fields such as respiratory disorders, cardiovascular disease (CVD), diabetes, cosmetology, and erectile dysfunction. Glaucoma comprises a group of eye diseases affecting the optic nerve, crucial for maintaining good vision.
The HP (high potency) APIs market research report is one of a series of new reports that provides HP (high potency) APIs market statistics, including HP (high potency) APIs industry global market size, regional shares, competitors with an HP (high potency) APIs market share, detailed HP (high potency) APIs market segments, market trends and opportunities, and any further data you may need to thrive in the HP (high potency) APIs industry. This HP (high potency) APIs market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenarios of the industry.
The market consists of sales of cytotoxic compounds and sex hormones. Values in this market are factory gate values, that is, the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors, and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.
The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD, unless otherwise specified).
The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.
This product will be delivered within 3-5 business days.
Table of Contents
1. Executive Summary2. HP (High Potency) APIs Market Characteristics3. HP (High Potency) APIs Market Trends and Strategies4. HP (High Potency) APIs Market - Macro Economic Scenario including the impact of Interest Rates, Inflation, Geopolitics and Covid and Recovery on the Market32. Global HP (High Potency) APIs Market Competitive Benchmarking and Dashboard33. Key Mergers and Acquisitions in the HP (High Potency) APIs Market34. Recent Developments in the HP (High Potency) APIs Market
5. Global HP (High Potency) APIs Growth Analysis and Strategic Analysis Framework
6. HP (High Potency) APIs Market Segmentation
7. HP (High Potency) APIs Market Regional and Country Analysis
8. Asia-Pacific HP (High Potency) APIs Market
9. China HP (High Potency) APIs Market
10. India HP (High Potency) APIs Market
11. Japan HP (High Potency) APIs Market
12. Australia HP (High Potency) APIs Market
13. Indonesia HP (High Potency) APIs Market
14. South Korea HP (High Potency) APIs Market
15. Western Europe HP (High Potency) APIs Market
16. UK HP (High Potency) APIs Market
17. Germany HP (High Potency) APIs Market
18. France HP (High Potency) APIs Market
19. Italy HP (High Potency) APIs Market
20. Spain HP (High Potency) APIs Market
21. Eastern Europe HP (High Potency) APIs Market
22. Russia HP (High Potency) APIs Market
23. North America HP (High Potency) APIs Market
24. USA HP (High Potency) APIs Market
25. Canada HP (High Potency) APIs Market
26. South America HP (High Potency) APIs Market
27. Brazil HP (High Potency) APIs Market
28. Middle East HP (High Potency) APIs Market
29. Africa HP (High Potency) APIs Market
30. HP (High Potency) APIs Market Competitive Landscape and Company Profiles
31. HP (High Potency) APIs Market Other Major and Innovative Companies
35. HP (High Potency) APIs Market High Potential Countries, Segments and Strategies
36. Appendix
Executive Summary
HP (High Potency) APIs Global Market Report 2025 provides strategists, marketers and senior management with the critical information they need to assess the market.This report focuses on hp (high potency) apis market which is experiencing strong growth. The report gives a guide to the trends which will be shaping the market over the next ten years and beyond.
Reasons to Purchase:
- Gain a truly global perspective with the most comprehensive report available on this market covering 15 geographies.
- Assess the impact of key macro factors such as conflict, pandemic and recovery, inflation and interest rate environment and the 2nd Trump presidency.
- Create regional and country strategies on the basis of local data and analysis.
- Identify growth segments for investment.
- Outperform competitors using forecast data and the drivers and trends shaping the market.
- Understand customers based on the latest market shares.
- Benchmark performance against key competitors.
- Suitable for supporting your internal and external presentations with reliable high quality data and analysis
- Report will be updated with the latest data and delivered to you along with an Excel data sheet for easy data extraction and analysis.
- All data from the report will also be delivered in an excel dashboard format.
Description
Where is the largest and fastest growing market for hp (high potency) apis? How does the market relate to the overall economy, demography and other similar markets? What forces will shape the market going forward? The hp (high potency) apis market global report answers all these questions and many more.The report covers market characteristics, size and growth, segmentation, regional and country breakdowns, competitive landscape, market shares, trends and strategies for this market. It traces the market’s historic and forecast market growth by geography.
- The market characteristics section of the report defines and explains the market.
- The market size section gives the market size ($b) covering both the historic growth of the market, and forecasting its development.
- The forecasts are made after considering the major factors currently impacting the market. These include:
- The forecasts are made after considering the major factors currently impacting the market. These include the Russia-Ukraine war, rising inflation, higher interest rates, and the legacy of the COVID-19 pandemic.
- Market segmentations break down the market into sub markets.
- The regional and country breakdowns section gives an analysis of the market in each geography and the size of the market by geography and compares their historic and forecast growth. It covers the growth trajectory of COVID-19 for all regions, key developed countries and major emerging markets.
- The competitive landscape chapter gives a description of the competitive nature of the market, market shares, and a description of the leading companies. Key financial deals which have shaped the market in recent years are identified.
- The trends and strategies section analyses the shape of the market as it emerges from the crisis and suggests how companies can grow as the market recovers.
Scope
Markets Covered:
1) By Type: Innovative HPAPI, Generic HPAPI2) By Synthesis Type: Synthetic HPAPI, Biotech HPAPI
3) By Therapeutic Application: Oncology, Hormonal Disorder, Glaucoma, Other Therapeutic Applications
Subsegments:
1) By Innovative HPAPI: Branded High Potency APIs; Newly Developed, Patented APIs2) By Generic HPAPI: Off-Patent High Potency APIs; Generic Versions of Innovative HPAPIs
Key Companies Mentioned: Merck KGaA; Pfizer, Inc; Thermo Fisher Scientific, Inc; Teva Pharmaceuticals; Lonza Group AG
Countries: Australia; Brazil; China; France; Germany; India; Indonesia; Japan; Russia; South Korea; UK; USA; Canada; Italy; Spain
Regions: Asia-Pacific; Western Europe; Eastern Europe; North America; South America; Middle East; Africa
Time Series: Five years historic and ten years forecast.
Data: Ratios of market size and growth to related markets, GDP proportions, expenditure per capita.
Data Segmentation: Country and regional historic and forecast data, market share of competitors, market segments.
Sourcing and Referencing: Data and analysis throughout the report is sourced using end notes.
Delivery Format: PDF, Word and Excel Data Dashboard.
Companies Mentioned
- Merck KGaA
- Pfizer, Inc
- Thermo Fisher Scientific, Inc
- Teva Pharmaceuticals
- Lonza Group AG
- Sanofi (EUROAPI)
- Corden Pharma International
- Dr. Reddy’s Laboratories Ltd.
- Siegfried Holding AG
- Novartis
- Roche India
- Arlak Biotech (India)
- Healthkind Labs Pvt. Ltd
- Swisschem Healthcare Pvt. Ltd
- Apikos Pharma
- Kolaz Biotech
- Cstone Pharma (China)
- Carsgen Therapeutics (China)
- Jw Therapeutics (China)
- Beigene(China)
- Takeda Pharmaceuticals (Japan)
- Astellas Pharma Inc (Japan)
- Otsuka Pharmaceutical Co, Ltd (Japan)
- Legend Biotech Co (China)
- Abbott Laboratories
- Vectura Group (U.K)
- Almedis (Russia)
- Neuca
- Farmacol
- Polska Grupa Farmaceutyczna
- Polpharma
- Tzmo
- Eli Lilly And Company
- Bristol-Myers Squibb Company
- Apotex
- Gilead Sciences
- Abbvie Inc
- Hisun Usa Inc
- GlaxoSmithKline
- Amega Biotech
- Biomarin Pharmaceutical
- Ferring Pharmaceuticals
- Tikun Olam Cannbit
- Wavelength Pharmaceuticals
- Saudibio
- Tabuk Pharmaceuticals
- Cipla
- Bayer
- Adcock Ingram
- Johnson & Johnson
- AstraZeneca Pharmaceutical (Pty) Ltd
- Eurolab
Table Information
| Report Attribute | Details |
|---|---|
| No. of Pages | 250 |
| Published | March 2025 |
| Forecast Period | 2025 - 2029 |
| Estimated Market Value ( USD | $ 27.47 Billion |
| Forecasted Market Value ( USD | $ 39.81 Billion |
| Compound Annual Growth Rate | 9.7% |
| Regions Covered | Global |
| No. of Companies Mentioned | 52 |
